Through its clinical trials, Capricor Therapeutics is actively engaged in the development of novel therapeutics to prevent and treat serious diseases.
INSPIRE
CompletedCapricor’s Phase 2 INSPIRE study enrolled patients who have a confirmed diagnosis of SARS-CoV-2.
HOPE-2
CompletedCapricor completed the HOPE-2 clinical trial for Capricor’s lead investigational therapy, CAP-1002.
HOPE
PHASE I/II enrollment completeThe Halt cardiomyOPathy progrEssion in Duchenne (HOPE) Phase I/II trial will evaluate CAP-1002 in patients with Duchenne muscular dystrophy associated cardiomyopathy.